SCHEMBL303692

SCHEMBL303692

CN1CCN(C(=O)c2ccc(N(Cc3ccccc3)S(=O)(=O)c3cn(C)cn3)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.66
HPGD P15428 3/20 0.54
KMT2A Q03164 3/20 0.54
GAA P10253 1/20 0.53
MEN1 O00255 2/20 0.53
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
FNTA P49354 3/20 0.47
FNTB P49356 3/20 0.47
ALDH1A1 P00352 1/20 0.46
NPC1 O15118 1/20 0.45
POLB P06746 2/20 0.45
LTB4R2 Q9NPC1 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PGGT1B P53609 2/20 0.44
OXTR P30559 1/20 0.43
GRM5 P41594 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722406 0.92 LMNA (0.58) LMNAHPGDKMT2AGAAMEN1
SCHEMBL3274787 0.89 LMNA (0.52) LMNAHPGDKMT2AGAAMEN1
SCHEMBL302045 0.88 SLC6A7 (0.53) LMNAHPGDKMT2AGAAMEN1
SCHEMBL3275527 0.88 LMNA (0.51) LMNAHPGDKMT2AGAAMEN1
SCHEMBL302272 0.87 KMT2A (0.51) LMNAHPGDKMT2AGAAMEN1
SCHEMBL1723243 0.87 LMNA (0.54) LMNAHPGDKMT2AGAAMEN1
SCHEMBL302686 0.86 LMNA (0.49) LMNAHPGDKMT2AGAAMEN1
SCHEMBL1722397 0.86 MEN1 (0.61) LMNAHPGDKMT2AMEN1FNTA
SCHEMBL1725046 0.86 LMNA (0.54) LMNAHPGDKMT2AGAAMEN1
SCHEMBL303115 0.86 LMNA (0.52) LMNAHPGDKMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885HPGD 3739/4885KMT2A 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.